

## Overview

These are generally benign in OD, requiring only supportive care. Mild sedation, ↑HR, & orthostatic hypoBP common. E.g. **Clozapine**, **risperidone**, **olanzapine**, **quetiapine**, **amisulpride**.

## Toxic mechanism

D<sub>2</sub>, 5HT, peripheral α<sub>1</sub>, H<sub>1</sub>, M<sub>1</sub> antagonism. Risperidone & amisulpride have ↓affinity for H<sub>1</sub>, M<sub>1</sub>.

## Toxicokinetics

**Clozapine, risperidone, olanzapine:** Rapidly abs. 1<sup>st</sup> pass metabolism - Cyt P450.

**Olanzapine:** Large Vd. Abs by SL route too and also has some hepatic conjugation to glucuronide.

**Quetiapine:** Large Vd. Protein bound. Hepatic met by Cyt P450

**Amisulpride:** 2 abs peaks (1hr, 4hr). Mod Vd. Most excreted unchanged in faeces & urine.

## Clinical features

**All but amisulpride:** Intoxication within 4hrs. Mild confusion, sedation, ↑HR, & orthostatic hypoBP common. Miosis. Coma & cardiotoxicity, rare. EPE more common in children.

**Clozapine:** Hypersalivation, anticholinergic effects (incl mydriasis). Fits in 5-10%.

**Olanzapine:** agitated delirium & urine retention common with mod OD. 15% have non-specific ST-T wave changes.

**Quetiapine:** <5% fit. Although may have ↑QT, torsade de pointes very rare.

**Amisulpride:** Higher risk of cardiotoxicity with ↑QT & ↓HR → ↑risk of torsade de pointes up to 36h. BBB possible. Coma uncommon. Large ingestions may delay onset of toxicity.

## Investigations

**Screening:** BSL, ECG, paracetamol

**Other:** Rpt ECG, cardiac monitoring. ↑QT can occur with some ODs. UEC if ECG abnormal.

## Risk assessment

**Clozapine & risperidone:** Usually benign. OD > 2.5mg/kg clozapine may → significant symptoms.

Olanzapine Dose	Effect
<40mg	Therapeutic sedation and antipsychotic effects
40-100mg (child > 0.5mg/kg)	Mild-mod sedation with possible anticholinergic effects
100-300mg	Sedation with intermittent marked agitation
>300mg	Coma possible, hypoBP with peripheral alpha blockade, rarely seizures
Quetiapine Dose	Effect
<3g	Mild-mod sedation and sinus tachycardia
≥3g	↑Risk of CNS depression, coma & ↓BP. Delirium or seizures possible
Amisulpride Dose	Effect
<8g	Mild-mod sedation and sinus tachycardia. ↑QTc & TdP reported >4g
8-15g	↑Risk of delayed CNS depression, cardiotoxicity (↓BP, ↑QRS, ↑QTc, BBB & TdP)
>15g	Expected delayed CNS depression, cardiotoxicity (↓BP, ↑QRS, ↑QTc, BBB & TdP)

## Management

**Resus, supportive care & monitoring:** ABCs incl. fluid management for ↓BP. Watch for urinary retention. Manage delirium with non-pharmacological & BDZ rather than **physostigmine**. Treat seizures with BDZ and acute dystonic reactions (EPE) with **benztropine** ± BDZ. Treat Na blockade cardiotoxicity with **bicarbonate** ± hyperventilation, and TdP with **MgSO<sub>4</sub>**/pacing.

**Decontamination:** Activated charcoal not advised except if >4g amisulpride ingested within 1-2h.

## Disposition

If remain asymptomatic at 4-6h (16h for amisulpride) post OD with normal ECG can be d/c else monitor until normal & below QT nomogram line. Advise child's parents of risk of EPE for 1wk.